HENDERSON, Nev.--(BUSINESS WIRE)--
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with
fully integrated commercial and drug development operations with a
primary focus in Hematology and Oncology, today announced that
independent director Luigi Lenaz, M.D., has been appointed to the newly
created position of Lead Director.
"Dr. Lenaz's unique scientific background and deep business expertise
make him ideally suited for the newly created Lead Director position,"
said Rajesh C. Shrotriya, M.D., Chairman and Chief Executive Officer of
Spectrum Pharmaceuticals. "Dr. Lenaz has provided invaluable advice
historically, and I look forward to working closely with him in his new
Luigi Lenaz, M.D., is a world-renowned oncologist and a leading
scientist authority in developing cancer drugs. An accomplished
oncologist before joining the industry, he has conducted research at
prominent institutions including Roswell Park Memorial Institute,
Memorial Sloan-Kettering Cancer Center, and the National Cancer
Institute in Milan. He is an experienced anti-cancer drug developer,
with over 40 years of experience in the pharmaceutical industry and has
played key roles in developing numerous major cancer drugs including
Taxol®, Adriamycin®, etoposide, amascrine,
cisplatin, and carboplatin. Dr. Lenaz served as a Post Doctoral Fellow
at both the Memorial Sloan-Kettering Cancer Center in New York and the
National Cancer Institute in Milan, Italy. He received his medical
degree at the University of Bologna Medical School in Bologna, Italy in
About Spectrum Pharmaceuticals, Inc.
Spectrum Pharmaceuticals is a leading biotechnology company focused on
acquiring, developing, and commercializing drug products, with a primary
focus in Hematology and Oncology. Spectrum currently markets six
hematology/oncology drugs, and has an advanced stage pipeline that has
the potential to transform the Company. Spectrum's strong track record
for in-licensing and acquiring differentiated drugs, and expertise in
clinical development have generated a robust, diversified, and growing
pipeline of product candidates in advanced-stage Phase 2 and Phase 3
studies. More information on Spectrum is available at www.sppirx.com.
Forward-looking statement — This press release may contain
forward-looking statements regarding future events and the future
performance of Spectrum Pharmaceuticals that involve risks and
uncertainties that could cause actual results to differ materially. These
statements are based on management's current beliefs and expectations.
These statements include, but are not limited to, statements that
relate to Spectrum's business and its future, including certain company
milestones, Spectrum's ability to identify, acquire, develop and
commercialize a broad and diverse pipeline of late-stage clinical and
commercial products, the timing and results of FDA decisions, and any
statements that relate to the intent, belief, plans or expectations of
Spectrum or its management, or that are not a statement of historical
fact. Risks that could cause actual results to differ include the
possibility that Spectrum's existing and new drug candidates may not
prove safe or effective, the possibility that our existing and new
applications to the FDA and other regulatory agencies may not receive
approval in a timely manner or at all, the possibility that our existing
and new drug candidates, if approved, may not be more effective, safer
or more cost efficient than competing drugs, the possibility that our
efforts to acquire or in-license and develop additional drug candidates
may fail, our dependence on third parties for clinical trials,
manufacturing, distribution and quality control and other risks that are
described in further detail in the Company's reports filed with the
Securities and Exchange Commission. The Company does not plan to
update any such forward-looking statements and expressly disclaims any
duty to update the information contained in this press release except as
required by law.
SPECTRUM PHARMACEUTICALS, INC.® is a
registered trademark of Spectrum Pharmaceuticals, Inc. and its affiliate.
REDEFINING CANCER CARE™ and the Spectrum Pharmaceuticals logos are
trademarks owned by Spectrum Pharmaceuticals, Inc. Any other
trademarks are the property of their respective owners.
© 2016 Spectrum Pharmaceuticals, Inc. All Rights Reserved
View source version on businesswire.com: http://www.businesswire.com/news/home/20161018005275/en/
Spectrum Pharmaceuticals, Inc.
Strategic Planning & Investor Relations
Source: Spectrum Pharmaceuticals, Inc.
News Provided by Acquire Media